📣 VC round data is live. Check it out!
- Public Comps
- Pulse Biosciences
Pulse Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pulse Biosciences and similar public comparables like UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP and more.
Pulse Biosciences Overview
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Founded
2014
HQ

Employees
75
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialPulse Biosciences Financials
Pulse Biosciences reported last 12-month revenue of $2M and negative EBITDA of ($57M).
In the same LTM period, Pulse Biosciences generated ($151K) in gross profit, ($57M) in EBITDA losses, and had net loss of ($78M).
Revenue (LTM)
Pulse Biosciences P&L
In the most recent fiscal year, Pulse Biosciences reported revenue of $350K and EBITDA of ($50M).
Pulse Biosciences is unprofitable as of last fiscal year, with gross margin of (54%), EBITDA margin of (14419%), and net margin of (20795%).
Financial data powered by Morningstar, Inc.
Pulse Biosciences Stock Performance
Pulse Biosciences has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Pulse Biosciences' stock price is $24.26.
Pulse Biosciences share price decreased by 2.9% in the last 30 days, and increased by 60.8% in the last year.
Pulse Biosciences has an EPS (earnings per share) of $-1.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -1.8% | -2.9% | 12.4% | 60.8% | $-1.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPulse Biosciences Valuation Multiples
Pulse Biosciences trades at 1056.5x EV/Revenue multiple, and (28.6x) EV/EBITDA.
EV / Revenue (LTM)
Pulse Biosciences Financial Valuation Multiples
As of June 3, 2026, Pulse Biosciences has market cap of $2B and EV of $2B.
Pulse Biosciences has a P/E ratio of (21.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pulse Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pulse Biosciences Margins & Growth Rates
Pulse Biosciences grew revenue by 800% and EBITDA by 29% in the last fiscal year.
In the most recent fiscal year, Pulse Biosciences reported gross margin of (54%), EBITDA margin of (14419%), and net margin of (20795%).
Pulse Biosciences Margins
Pulse Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pulse Biosciences Operational KPIs
Pulse Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Pulse Biosciences' Rule of 40 is (1260%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pulse Biosciences' Rule of X is (60%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pulse Biosciences Competitors
Pulse Biosciences competitors include UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP, 4DMedical, Qingdao Baheal Medical, Draegerwerk, BoneSupport, Oxford Nanopore Technologies and Embla Medical.
Most Pulse Biosciences public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.0x | 2.9x | 15.0x | 14.4x | |||
| 18.2x | - | 45.1x | - | |||
| 4005.2x | - | (93.6x) | - | |||
| 22.3x | 21.1x | 117.5x | 110.9x | |||
| 388.4x | 325.4x | (90.4x) | (13.6x) | |||
| 1.6x | 1.6x | 12.8x | 12.8x | |||
| 0.4x | 0.4x | 3.9x | 3.8x | |||
| 11.9x | 10.7x | 57.4x | 44.0x | |||
This data is available for Pro users. Sign up to see all Pulse Biosciences competitors and their valuation data. Start Free Trial | ||||||
Pulse Biosciences VC Funding History
Before going public, Pulse Biosciences raised $8M in total equity funding, across 1 round.
Last private valuation of Pulse Biosciences was $20M, after raising $8M in November 2014.
Pulse Biosciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pulse Biosciences
| When was Pulse Biosciences founded? | Pulse Biosciences was founded in 2014. |
| Where is Pulse Biosciences headquartered? | Pulse Biosciences is headquartered in United States. |
| How many employees does Pulse Biosciences have? | As of today, Pulse Biosciences has over 75 employees. |
| Who is the CEO of Pulse Biosciences? | Pulse Biosciences' CEO is Paul A. Laviolette. |
| Is Pulse Biosciences publicly listed? | Yes, Pulse Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Pulse Biosciences? | Pulse Biosciences trades under PLSE ticker. |
| When did Pulse Biosciences go public? | Pulse Biosciences went public in 2016. |
| Who are competitors of Pulse Biosciences? | Pulse Biosciences main competitors include UFP Technologies, Beijing Balance Medical, Heron Neutron Medical, MicroPort EP, 4DMedical, Qingdao Baheal Medical, Draegerwerk, BoneSupport, Oxford Nanopore Technologies, Embla Medical. |
| What is the current market cap of Pulse Biosciences? | Pulse Biosciences' current market cap is $2B. |
| What is the current revenue of Pulse Biosciences? | Pulse Biosciences' last 12 months revenue is $2M. |
| What is the current revenue growth of Pulse Biosciences? | Pulse Biosciences revenue growth (NTM/LTM) is 363%. |
| What is the current EV/Revenue multiple of Pulse Biosciences? | Current revenue multiple of Pulse Biosciences is 1056.5x. |
| Is Pulse Biosciences profitable? | No, Pulse Biosciences is not profitable. |
| What is the current EBITDA of Pulse Biosciences? | Pulse Biosciences has negative EBITDA and is not profitable. |
| What is Pulse Biosciences' EBITDA margin? | Pulse Biosciences' last 12 months EBITDA margin is (3693%). |
| What is the current EV/EBITDA multiple of Pulse Biosciences? | Current EBITDA multiple of Pulse Biosciences is (28.6x). |
| How many companies Pulse Biosciences has acquired to date? | Pulse Biosciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Pulse Biosciences has invested to date? | Pulse Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Pulse Biosciences
Lists including Pulse Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.